Does Wegovy show up in blood tests?

Will a routine blood test pick up Wegovy by name?

No. The blood tests your GP or a private clinic orders (a full blood count, a lipid panel, kidney function, thyroid screen, HbA1c) are looking for specific physiological markers, not for drug molecules. Semaglutide is not on the list of substances those panels screen for. So the short answer, if a friend, employer or insurer has asked you this, is that Wegovy will not appear on standard blood work as a named drug.

Dedicated pharmaceutical drug testing does exist (specialist toxicology used in clinical research or certain medical contexts) but that bears no resemblance to the blood draws most people ever encounter. If you want a fuller picture of how semaglutide behaves in the body before treatment, the semaglutide overview on our site covers the mechanism in plain terms.

One practical check worth doing in under a minute: pull up the letter or portal note from your last blood test and look at what was actually requested. You will almost certainly see terms like 'LFTs', 'eGFR', 'lipid profile' or 'HbA1c', none of which involve testing for a GLP-1 medicine. We also have a dedicated page on whether semaglutide will show up in a blood test if you want to explore that question in more depth.

Which blood markers can Wegovy actually change?

This is where it gets more clinically interesting. Even though Wegovy is invisible to standard panels as a substance, its effects on your body are not. The NHS semaglutide medicines page notes that GLP-1 receptor agonists slow gastric emptying and reduce appetite, and those mechanisms ripple outward into several measurable markers.

Blood glucose and HbA1c often fall during treatment, sometimes meaningfully, particularly if you started with prediabetes or type 2 diabetes. Cholesterol and triglyceride readings can improve. Liver enzyme levels (ALT, AST) sometimes drop alongside weight loss. Blood pressure, while not a blood test, tends to fall too, which can affect whether a GP decides to adjust other medicines.

None of this is alarming; in fact these shifts are usually positive. The point is that your GP needs the context. If your cholesterol has improved significantly and your doctor does not know you are on Wegovy, they may attribute the change to something else, or miss that a dose of a statin could now be reviewed. Disclosure is not a formality; it is clinically useful. You can read more about what the treatment involves on our Wegovy information page.

Does it matter if your prescriber knows you are taking it?

Yes, and for reasons beyond blood tests. The NHS England guidance on weight-management injections makes clear that GP notification is part of responsible prescribing practice, and at nume, a GPhC-registered Independent Prescriber reviews every consultation personally, with GP notification in line with that guidance.

For your blood results specifically, the practical implication is simple: flag Wegovy on any health form or questionnaire, and mention it verbally at any appointment where blood tests are ordered or reviewed. A clinician interpreting a lower HbA1c or a changed lipid panel without knowing you are on a GLP-1 medicine may draw the wrong conclusion about your underlying health or medication needs. If you are considering treatment and want to understand what monitoring looks like in practice, our free consultation is the right starting point, a prescriber can talk through exactly what to expect from your results.

There is also a broader point worth making. Questions about blood tests sometimes come up in the context of employment or insurance screening, and our page on whether semaglutide shows up in a blood test addresses those concerns directly. But if you are ever directly asked by a medical examiner whether you take prescription medicines, the honest and legally correct answer is yes. That is unrelated to what any blood test can detect.

What if you are switching from another treatment or have existing blood conditions?

People transferring to Wegovy from another weight-loss medicine, or those with existing liver or kidney conditions, sometimes wonder whether their blood results create a barrier. That is a clinical question, not one a website can resolve. What is useful to know is that conditions such as non-alcoholic fatty liver disease (where liver enzyme readings are often elevated) are among those that can improve with significant weight loss, and semaglutide is now being studied in this context. The MHRA approved semaglutide for a specific form of fatty liver disease (MASH) in July 2026, as reported on the GOV.UK news announcement.

If you have had blood tests flagged as abnormal and want to understand whether Wegovy is still appropriate, that is exactly the kind of nuance a prescriber needs to assess. A broader look at weight-loss treatment options may also help if you are weighing up different routes, and if cost is part of your thinking, our page on Wegovy prive sets out the pricing picture clearly. For those already on treatment and curious about related questions, whether semaglutide shows up in urine tests is another question we have covered separately.